Stay updated on Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial
Sign up to get notified when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.

Latest updates to the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed treatment protocols for a clinical trial involving pembrolizumab and the addition of new collaborators and a revision number. Notably, the core content regarding the trial's eligibility criteria and treatment regimen has been deleted.SummaryDifference22%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 6, 2025.SummaryDifference0.2%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check59 days agoChange DetectedThe webpage has been updated to include new results and metrics related to patient outcomes, specifically detailing the Quality of Life assessments using EORTC QLQ-C30 and EORTC QLQ-H&N35 questionnaires, as well as updated reporting dates for results. Notably, previous metrics such as Overall Response Rate and Clinical Benefit Rate have been removed.SummaryDifference58%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Reirradiation With Pembrolizumab in Head-and-Neck Clinical Trial page.